The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I trial of chemoimmunotherapy combining bacillus Calmette-Guerin (BCG) and intravesical gemcitabine for patients with BCG-relapsing high-grade nonmuscle-invasive bladder cancer.
 
Manuel R. De Jesus Escano
No Relationships to Disclose
 
Daniel D. Sjoberg
No Relationships to Disclose
 
Melissa McCarter
No Relationships to Disclose
 
Marlena McGill
No Relationships to Disclose
 
Alvin Goh
No Relationships to Disclose
 
Timothy F. Donahue
No Relationships to Disclose
 
S. Machele Donat
No Relationships to Disclose
 
Eugene K. Cha
No Relationships to Disclose
 
Harry W. Herr
No Relationships to Disclose
 
Anoop M. Meraney
No Relationships to Disclose
 
Hikmat A Al-Ahmadie
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; EMD Serono; Janssen Biotech
 
David B. Solit
Stock and Other Ownership Interests - Loxo
Consulting or Advisory Role - BridgeBio Pharma; Illumina; Lilly; Loxo; Pfizer; QED Therapeutics; Vividion Therapeutics
 
Guido Dalbagni
No Relationships to Disclose
 
Dean F. Bajorin
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Dragonfly Therapeutics; Fidia Farmaceutici S. p. A.; Merck; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas (Inst)
Travel, Accommodations, Expenses - Merck; Roche/Genentech
 
Bernard H. Bochner
No Relationships to Disclose
 
Eugene J. Pietzak
Honoraria - UpToDate
Consulting or Advisory Role - Chugai Pharma; Merck; QED Therapeutics